EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rilzabrutinib for the Treatment of Immune Thrombocytopenia

Caterina Labanca, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese iD, Francesco Mendicino, Giulio Caridà, Eugenio Lucia, Virginia Olivito, Veronica Manicardi, Nicola Amodio, Antonino Neri, Fortunato Morabito iD und 1 weitere

European Journal of Haematology · 2025-07 · 115 (1) · 4-15

DOI: 10.1111/ejh.14425 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 13.04.2025. Verfasst von Caterina Labanca und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Protein Kinase Inhibitors, Pyrimidines, Nitriles. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advancements in the understanding of ITP pathogenesis have led to significant improvements in disease management through the use of both traditional immunosuppressive strategies and novel targeted therapies. However, a subset of patients remains refractory to treatment or achieves only transient benefits, underscoring the need for alternative therapeutic approaches. Bruton's tyrosine kinase (BTK) inhibitors have emerged as a promising strategy for autoimmune cytopenias, including ITP, due to their ability to modulate key immune pathways. Rilzabrutinib, an oral, reversible BTK inhibitor, represents a novel therapeutic approach for ITP. Rilzabrutinib, an oral, reversible BTK inhibitor, offers a novel mechanism of action by preserving platelet aggregation while reducing macrophage‐mediated platelet clearance, distinguishing it from irreversible BTK inhibitors. This review provides an updated and comprehensive analysis of the Phase 1/2 LUNA 2 trial and its long‐term extension, contextualizing rilzabrutinib within the broader treatment landscape. We also offer a comparative assessment of other BTK inhibitors investigated for ITP and discuss rilzabrutinib's potential positioning relative to existing therapies, including thrombopoietin receptor agonists (TPO‐RAs), rituximab, fostamatinib, and immunosuppressants. Results from the phase 1/2 LUNA 2 trial and its long‐term extension demonstrated that Rilzabrutinib induced a durable platelet response in 40% of patients, with a median time to response of 11.5 days. The treatment exhibited a favorable safety profile, with predominantly grade 1 or 2 adverse events and no significant safety concerns commonly associated with BTK inhibitors, such as increased bleeding risk, hepatic toxicity, or cardiac arrhythmias. Preliminary data presented at ASH 2024 from the ongoing Phase 3 LUNA 3 trial, a randomized, double‐blind study, further support rilzabrutinib's efficacy and long‐term safety. If confirmed, these findings suggest that rilzabrutinib could represent a valuable therapeutic option for patients with refractory ITP , addressing a critical unmet need and potentially redefining treatment paradigms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicProtein Kinase InhibitorsPyrimidinesNitrilesHumansAgammaglobulinaemia Tyrosine KinaseTreatment Outcome

Stichwörter der Autor:innen

Bruton's tyrosine kinase inhibitorplatelet responserefractory immune thrombocytopeniarilzabrutinib

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPyrimidinesNitrilesBTK protein, human

Autor:innen und Institutionen

  • Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
  • Laboratorio di Ricerca Traslazionale, Azienda USL-IRCSS Reggio Emilia, Reggio Emilia, Italy.
  • Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy.
  • Scientific Directorate, IRCCS of Reggio Emilia, Reggio Emilia, Italy.
  • Gruppo Amici Dell'ematologia Foundation-GrADE, Reggio Emilia, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

ORCID-Profile: Antonella Bruzzese, Fortunato Morabito

Zitieren

APA

Labanca, C., Martino, E. A., Vigna, E., Bruzzese, A., Mendicino, F., Caridà, G., Lucia, E., Olivito, V., Manicardi, V., Amodio, N., Neri, A., Morabito, F., & Gentile, M. (2025). Rilzabrutinib for the Treatment of Immune Thrombocytopenia. European Journal of Haematology, 115(1), 4-15. https://doi.org/10.1111/ejh.14425

Vancouver

Labanca C, Martino EA, Vigna E, Bruzzese A, Mendicino F, Caridà G, et al. Rilzabrutinib for the Treatment of Immune Thrombocytopenia. European Journal of Haematology. 2025;115(1):4-15. doi:10.1111/ejh.14425

BibTeX
@article{Labanca2025,
  author = {Labanca, Caterina and Martino, Enrica Antonia and Vigna, Ernesto and Bruzzese, Antonella and Mendicino, Francesco and Caridà, Giulio and Lucia, Eugenio and Olivito, Virginia and Manicardi, Veronica and Amodio, Nicola and Neri, Antonino and Morabito, Fortunato and Gentile, Massimo},
  title = {Rilzabrutinib for the Treatment of Immune Thrombocytopenia},
  journal = {European Journal of Haematology},
  year = {2025},
  volume = {115},
  number = {1},
  pages = {4--15},
  doi = {10.1111/ejh.14425}
}
Kostenlos starten →